Bioson CEO Lee Doohyun Strengthens Control Over Lumimicro

LumiMicro Major Shareholder Voltia Signs 20 Billion KRW Convertible Bond Call Option Contract
CEO Lee Doohyun Continues Expanding LumiMicro Stake with 1.3 Million Shares Bought on Market
Voltia, Vibozone, and CEO Lee Doohyun Rise as LumiMicro's Largest Shareholders

[Asia Economy Reporter Park Hyungsoo] Voltia announced that it has signed a call option contract on the convertible bonds of Lumimicro held by Aprogen KIC.

Lumimicro announced on the 29th that its largest shareholder, Voltia, signed an option contract on the 20 billion KRW scale 9th series convertible bonds of Lumimicro held by Aprogen KIC.

CEO Lee Doohyun of Vivoson previously secured management rights of Lumimicro by investing a total of 35 billion KRW, including 20 billion KRW from Voltia and 15 billion KRW from Vivoson, in December last year. At the end of January this year, Vivoson additionally acquired convertible bonds worth 20 billion KRW. CEO Lee purchased 971,464 shares on the market by the 13th and an additional 328,536 shares by the 16th, further increasing his stake and strengthening control over Lumimicro.

Based on the call option contract secured through Voltia, when converted into common shares, the number of Lumimicro shares held by Voltia, Vivoson, and CEO Lee Doohyun will increase by 14,285,714 shares to a total of 26.3 million shares.

Including the convertible bonds held by Vivoson and the call option acquisition contract worth 5 billion KRW signed by Voltia, a total of 51,120,650 shares will be secured.

A Vivoson official stated, "CEO Lee Doohyun's confidence in growing Vivoson into a global healthcare company is reflected in the additional acquisition of Lumimicro shares," and added, "Please watch how Lumimicro and Vivoson will maximize synergy in various ways."

Vivoson is currently conducting global Phase 3 clinical trials for its core pipeline, the non-opioid analgesic Opiranserin (VVZ-149). They held a kickoff meeting with the clinical CRO and plan to recruit patients around July together with the US clinical team.

Expectations for Vivoson's backdoor listing through Lumimicro are increasing.

This content was produced with the assistance of AI translation services.